Programmable self-replicating JEV nanotherapeutics redefine RNA delivery in ALS

Area of Science:

• Neuroscience
• Virology
• Gene Therapy

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options.
• Effective delivery of therapeutics to the central nervous system (CNS) is a major hurdle for ALS gene therapy.
• Antisense oligonucleotides (ASO) and CRISPR/Cas9 show promise but require efficient delivery vectors.

Purpose of the Study:

• To propose a novel strategy for targeted therapeutic delivery to motor neurons in the CNS.
• To explore the use of engineered Japanese encephalitis virus (JEV) as a nanocarrier for ASO delivery.
• To overcome the blood-brain and blood-spinal cord barriers (BBB/BSCB) for enhanced gene therapy in neurodegenerative diseases.

Main Methods:

• Engineering Japanese encephalitis virus (JEV) to act as a self-replicating nanocarrier.
• Incorporating antisense oligonucleotide (ASO) sequences into the JEV genome for co-packaging.
• Utilizing JEV's natural neurotropism and immune cell-mediated entry for CNS targeting.
• Employing microRNA (miRNA)-mediated attenuation for enhanced safety and CNS specificity.

Main Results:

• The proposed JEV-based nanocarrier system theoretically enables targeted ASO delivery to motor neurons.
• This approach leverages JEV's properties to bypass the BBB/BSCB, facilitating CNS penetration.
• Co-packaging of ASO within the JEV genome allows for sustained therapeutic release.

Conclusions:

• Engineered JEV presents a potential paradigm shift for CNS gene therapy in ALS and other neurodegenerative conditions.
• This strategy offers a theoretical framework for efficient, targeted, and sustained ASO delivery.
• Experimental validation is crucial to confirm the safety and therapeutic efficacy of this approach.